ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

GENF Genflow Biosciences Plc

3.10
0.00 (0.00%)
14 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Genflow Biosciences Plc LSE:GENF London Ordinary Share GB00BP2C3V08 ORD GBP0.0003
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.10 3.00 3.20 3.10 3.10 3.10 554,877 07:31:08
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Coml Physical, Biologcl Resh 169k -1.63M -0.0056 -5.54 9.07M
Genflow Biosciences Plc is listed in the Coml Physical, Biologcl Resh sector of the London Stock Exchange with ticker GENF. The last closing price for Genflow Biosciences was 3.10p. Over the last year, Genflow Biosciences shares have traded in a share price range of 1.35p to 3.55p.

Genflow Biosciences currently has 292,506,618 shares in issue. The market capitalisation of Genflow Biosciences is £9.07 million. Genflow Biosciences has a price to earnings ratio (PE ratio) of -5.54.

Genflow Biosciences Share Discussion Threads

Showing 1251 to 1274 of 1275 messages
Chat Pages: 51  50  49  48  47  46  45  44  43  42  41  40  Older
DateSubjectAuthorDiscuss
12/6/2024
07:12
12 June 2024



Genflow Biosciences Plc



Receipt of Grant Funding



Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce receipt of €395,847 representing 50% of the Exofastrack research grant from the Government of Wallonia in Belgium's Advanced Therapy Medicinal Products (ATMPs).



The grant, a non-dilutive, non-reimbursable subsidy, supports Genflow and EXO Biologics' 3-year scientific program. Covering 80% of the expenses, the grant will be used for working capital. The program (see press release here) will deliver a therapeutic product composed of exosomes encapsulating an AAV or mRNA encoding SIRT6. The exosome therapy will be designed to target liver fibrosis (MASH) and Werner Syndrome, an accelerated aging disease.



Dr. Eric Leire, CEO of Genflow commented: "We are thrilled to receive this grant from the Government of Wallonia. This funding will significantly advance our research program focused on exosome-based therapies, potentially leading to groundbreaking treatments for liver fibrosis and Werner Syndrome. Our commitment to pioneering therapeutic solutions for longevity is further strengthened by this support, and we look forward to the impactful developments that will emerge from this collaboration."

moneymunch
11/6/2024
13:28
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,633 followers
56m

A recent Prevention article pointed to daily exercise and a diet high in fruits & vegetables as ways to increase your #lifespan.

These measures do offer moderate improvements, yet #biotech research promises a much more significant extension. Genflow Biosciences (LON:GENF) (OTCQB:GENFF) promising #SIRT6 research is an example of research conducted that could combat aging and its symptoms.

Coupled with our growing IP portfolio, it’s no wonder The Guardian named us a firm to watch in 2024!

Read the Prevention article to learn how to extend your #healthspan in the meantime:

#aging #healthspan #GENF

moneymunch
10/6/2024
16:37
Plenty of chunky trades under the radar, looks like the share accumulation continues. Gla holders...Big news at anytime!!! ;-)
moneymunch
07/6/2024
08:38
News on Monday from Eric would be very timely. Gla holders:-)


10th - 11th June 2024 - Organised by Longevity Technology who hold 3% of Genflow, the advisory panel includes Eric Verdin who sits on Genflow's Scientific Advisory Board, Aubrey de Grey who originally was a member of Genflow's SAB and Jim Mellon who was an investor in Genflow's IPO....All bodes well!!! Gla ;-)


New international event program launches to bring longevity entrepreneurs and investors together.

Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.

moneymunch
06/6/2024
17:21
Cheap shares accumulated, the big players continue to mop up the few shares in free float....Gla holders, they want your shares!!! :-)

Ps those hoping to get back in sub 3p are going to be greatly disappointed i reckon , with news at anytime getting closer and closer. ...On and UP!!! :-)

moneymunch
05/6/2024
17:52
Highly relevant and exciting for the prospects and potential of Genflow's AAV gene therapy R&D. Gla :-)



In a First, AAV-Based Gene Therapy Restores Hearing in Both Ears of Children with Hereditary Deafness.

5/6/24

moneymunch
05/6/2024
10:31
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,623 followers

16h

Aging is not only a societal challenge but also an #economic one. As the number of Americans over the age of 65 rises, so do the costs associated with healthcare.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is filled with committed researchers who are working to lighten aging's financial burden.

#GENF offers:
↗️ research focusing on #centenarian variant of the #SIRT6 gene
↗️ promising, innovative treatments for a variety of illnesses
↗️ scientific advisory board is filled with dedicated & committed researchers

Make sure to take a look at National Library of Medicines take on the economic implications of aging :

#aging #healthspan

moneymunch
05/6/2024
08:47
Perfectly poised and primed, as the spring becomes coiled in anticipation of the next UPdate and significant move North. Gla holders:-)
moneymunch
04/6/2024
07:19
Cutting edge science with patents pending, compelling preclinical data progressing to human clinical trials, prestigious academic partners and a leading influential and distinguished hands on Scientific Advisory Board.

Exponential upside potential and prospects!!!

Will a Major Pharma/JV partner wait for positive trial results from Genflow's Nash Human Clinical Phase 1/2 trials planned for next year, or will one move early given how hot the Nash/Liver space is right now, as well as the promise of a rapidly expanding and evolving longevity market and the compelling nature of SIRT6's profound importance and influence over multiple disease targets associated with aging.

Big news could at anytime, and any in time for next weeks event would certainly put Genflow centre stage.


10th - 11th June 2024 - Organised by Longevity Technology who hold 3% of Genflow, the advisory panel includes Eric Verdin who sits on Genflow's Scientific Advisory Board, Aubrey de Grey who originally was a member of Genflow's SAB and Jim Mellon who was an investor in Genflow's IPO....All bodes well!!! Gla ;-)


New international event program launches to bring longevity entrepreneurs and investors together.

Founders Forum and Longevity.Technology today announced the launch of the Founders Longevity Forum, a premier event series designed to educate and connect investors with the vast potential within the longevity market.

The inaugural Founders Longevity Forum will take place at Olympia London during the renowned London Tech Week, focusing on a sector that is projected to exceed $600 billion by 2025. This partnership aims to foster meaningful connections between startups, venture capitalists (VCs), corporate venture capitalists (CVCs), family offices and CEOs leading the charge in longevity.

Brent Hoberman, Co-Founder and Executive Chair of Founders Forum Group, said: “Longevity is becoming a mega trend as science makes increased healthspans more realistic, converging with a wider shift towards preventative healthcare.

“We’ve noticed a need to connect top scientists and innovative startups with funds to help them turn their dreams into reality. By bringing together the best and brightest minds working on longevity today, we can galvanize progress in this area and transform the demographic landscape.”

Taking place on New international event program launches to bring longevity entrepreneurs and investors together.4, the Founders Longevity Forum will address the investment opportunities across the longevity space, from established longevity business models such as diagnostics, longevity clinics and supplements, through to cutting-edge longevity biotech companies poised to revolutionize the biotech industry and transform society.

The event will also benefit from an advisory panel that has decades of longevity and geroscience expertise between them; the panel includes Eric Verdin, Andrea Maier, Jim Mellon and Aubrey de Grey, with further members to be announced.

“Multiple longevity events are happening and they’re all great, but few are specifically focused on bringing more investors into this rapidly accelerating field,” said Phil Newman, Founder and CEO, Longevity.Technology.

“We plan to stage events in London, Abu Dhabi and San Francisco initially to accelerate longevity investment globally, and catalyze a wave of innovation and collaboration that will redefine the future of human health.”

“We’re keen to educate investors on the vast opportunities in longevity whilst fostering meaningful connections for startups and scaleups in this niche,” said Carolyn Dawson, CEO, Founders Forum Group.

“Helping create these connections is central to our mission at Founders Forum Group as we seek to empower entrepreneurs at every stage of their journeys; with Longevity.Technology as our partner, we can forge formative alliances that propel longevity innovation.”

moneymunch
03/6/2024
08:20
Looks like we have forward momentum again. Would be great to see us back over 4p this week.
felchandbart
03/6/2024
07:04
RNS Number : 7241Q
Genflow Biosciences PLC
03 June 2024




3 June 2024

Genflow Biosciences Plc

Notice of Annual General Meeting

Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company") an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases is pleased to announce that it will hold its Annual General Meeting ("AGM") at 12pm on Thursday 27 June 2024 at 1 Heddon Street, London, W1B 4BT.

The Notice of the AGM ("Notice") and 2024 Form of Proxy will shortly be available on the Company's website, www.genflowbio.com, and have, where applicable, been posted to shareholders. Further details of the arrangements for this year's AGM are set out in the Notice.

As announced on 7 May 2024, the Company's Annual Report and Accounts for the year ended 31 December 2023 are also available on the website and has, where applicable, also been posted to registered shareholders.

moneymunch
02/6/2024
18:08
I'm not expecting any announcement because of the conference. It would be highly unusual to do this and make a presentation although Vera is speaking tonight so it would t be breaking any market rules, I think. Anyhow, no rns and some will sell on no news. Good luck to them, but I'm here for the long haul.Marmie
marmiesz
01/6/2024
17:52
The conference starts tomorrow and so it would be amazing to get news on Monday, although regardless, I'm still sure June will see a significant re-rate as important news is delivered. Gla :')

"focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research"

moneymunch
01/6/2024
07:57
Maybe incoming news at next weeks conference from Vera's SIRT6 studies at University of Rochester. Gla ;-)

Systems Modeling, Aging Biomarkers, and Longevity Interventions


Systems Aging Gordon Research Conference


June 2 - 7, 2024

The Systems Aging GRC is a premier, international scientific conference focused on advancing the frontiers of science through the presentation of cutting-edge and unpublished research, prioritizing time for discussion after each talk and fostering informal interactions among scientists of all career stages.



Keynote Session: Molecular Approaches in Age Reversal Research

Discussion Leader: Vera Gorbunova (University of Rochester, United States)

moneymunch
31/5/2024
13:14
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)

1,618 followers
1d

For the first time since 2020, US life expectancy has increased.

Genflow Biosciences (LON:GENF) (OTCQB:GENFF) is dedicated to ensuring that #healthspan grows alongside lifespan. Our groundbreaking research surrounding #SIRT6 mutations could revolutionize how we age and ensure we live healthier for longer.

Learn more about our research:

moneymunch
31/5/2024
13:12
I reckon we're going to see a decent re-rate this coming month on the back of important news and so I'd be surprised at anything sub 3p going forward...Big players are accumulating for big things to come and every chance of US institutional investors awaiting in the wings...Genflow's prospects and potential suggest the journey from small cap to mid cap is well underway. Gla :-)
moneymunch
31/5/2024
10:57
Early stage UK Biotech M & A on the rise. Gla:-)

Genetic Engineering & Biotechnology News

Merck to Acquire UK Biotech EyeBio for Up to $3B, Re-Entering Eye Drug Space

May 29, 2024

Merck & Co. has agreed to acquire EyeBiotech (EyeBio) for up to $3 billion, the companies said today, in a deal that will return the buyer to the eye drug development segment it vacated about a decade ago.

Based in London, EyeBio has developed a pipeline of clinical and preclinical candidates designed to prevent and treat vision loss associated with retinal vascular leakage. EyeBio’s lead candidate Restoret™ (EYE103) is a tetravalent, tri-specific antibody agonist of the Wingless-related integration site (Wnt) signaling pathway.

moneymunch
30/5/2024
14:21
Please check your facts bri15. GENF is not an AIM stock.Marmie
marmiesz
30/5/2024
14:03
Just a few small profit takers that have taken the price back down, and of no concern imho....this will bounce big in June as the share accumulation by the bigger players continues, with plenty of material newsflow expected. Hold on tight for the next re-rate or two in the coming weeks. Gl :-)
moneymunch
30/5/2024
13:41
The whole market is flaky very difficult to understand, its driving me mad
jakes114
30/5/2024
08:39
Just the start of Genflow’s stellar UPside journey. Gla holders:-)
moneymunch
30/5/2024
08:14
Excellent news! Can see this getting a further charge on today.
felchandbart
30/5/2024
07:36
Sarcopenia, another area of Genflow’s pipeline that could be of huge interest to a Major Pharma JV partner. Gla :-)

27/5/24

moneymunch
30/5/2024
07:24
This and Verici DX (vrci)are going to be big money makers for shareholders,I going to be adding more funds in both today.
bri15
Chat Pages: 51  50  49  48  47  46  45  44  43  42  41  40  Older

Your Recent History

Delayed Upgrade Clock